| City of Hope |
|
Precision BioSciences, Inc. |
Cancer - Lymphoma |
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL |
Recruiting |
|
| City of Hope |
|
Novartis Pharmaceuticals |
Cancer - Lymphona |
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) |
Recruiting |
|
| City of Hope |
|
Glaxo Smith Kline (GSK) |
Cancer - Lung |
Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
Recruiting |
|
| City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
| City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
| City of Hope |
|
Torque Therapeutics, Inc. |
Cancer - Lymphoma |
TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas |
Recruiting |
|
| UCSF |
|
Department of Defense |
Acute Respiratory Distress Syndrome (ARDS) |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma |
Recruiting |
|
| UCSF |
|
Case Western Reserve University |
HIV |
A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) |
Recruiting |
|
| UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
| UCSF |
|
PACT Pharma |
Cancer – Solid Tumor |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors |
Recruiting |
|
| UCSF & UC Davis |
|
|
COVID-19/ARDS |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
Recruiting |
|
| UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease |
Recruiting |
|
| UCI |
|
Pluristem Ltd. |
Intubated COVID-19 patients |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 |
Recruiting |
|
| UCI & UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Recruiting |
|
| UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
| UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Recruiting |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
Recruiting |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
Recruiting |
|
| UC Davis & UCSD & UCI & UCSF & City of Hope |
|
Pact Pharma & CIRM |
Solid tumors |
A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered As A Single Agent Or In Combination With Anti PD-1 To Patients With Locally Advanced Or Metastatic |
Recruiting |
|
| UC Davis |
|
Orca Biosystems Inc. |
Hematologic Malignancies |
A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) |
Recruiting |
|
| UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
|
| UC Davis |
|
Capricor Therapeutics |
Duchenne Muscular Dystrophy |
Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) |
Recruiting |
|
| UC Davis |
|
Cabaletta |
Pemphigus Vulgaris |
Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris |
Recruiting |
|
| UC Davis |
|
Eureka Therapeutics |
Hepatocellular Carcinoma |
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) |
Recruiting |
|
| UCSF & UCSD & CIRM |
|
CIRM |
ARDS/COVID |
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) |
Recruiting |
|
| UC Davis & UCSD |
|
Viacyte |
Type 1 diabetes |
An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
Recruiting |
|
| UC Davis |
|
Autolus |
Acute Lymphoblastic Leukaemia |
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia |
Recruiting |
|
| UC Davis |
|
AlloVir |
Kidney transplant |
Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with |
Recruiting |
|
| UC Davis |
|
Atara Bio |
Hematologic Malignancies |
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases |
Recruiting |
|
| UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
|
| UCSF |
|
CRISPR Therapeutics |
B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL |
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies |
Recruiting |
|
| UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
Recruiting |
|
| UCSF |
|
Poseida Therapeutics, Inc. |
Prostate cancer |
A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
Recruiting |
|
| UCSF |
|
Allo Vir, Inc. |
BK Viremia in Kidney Transplant Recipients |
Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients |
Recruiting |
|
| UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
Recruiting |
|
| UCSF |
|
Passage Bio Inc. |
GM1 Gangliosidosis |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant |
Recruiting |
|
| UCSF |
|
Editas Medicine Inc. |
Sickle Cell Disease |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D |
Recruiting |
|
| UCSF |
|
Jasper Therapeutics |
Severe Combined Immunodeficiency syndrome |
A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID |
Recruiting |
|
| UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Recruiting |
|
| City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) |
No longer active |
|
| UCI |
|
ImmunoCellular Therapeutics |
Cancer - Brain |
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma |
No longer active |
|
| UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
| UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
| UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
| UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) |
No longer active |
|
| City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Long-Term Follow-up Study for Patients Previously Treated With JCAR015 |
No longer active |
|
| UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
